Tufts Medical Center researchers in a recent article published in Value in Health found that the Institute for Clinical and Economic Review (ICER) makes ‘modest’ revisions between its draft and revised evidence reports based on industry comments.
The researchers reviewed 15 reports by ICER between 2017-19.
“Changes in ICER’s estimates of cost-effectiveness between its draft and revised evidence reports are generally modest,” they write. “Greater precision in industry comments could increase the influence of industry critiques, thus enhancing the dialogue around pharmaceutical value.”
To read the article, click here.